News

Preclinical Research with Advanced Oncology Models and Immuno-oncology Services by Altogen Labs

Altogen Labs is a preclinical research organization specializing in the testing and evaluation of novel pharmacological and biological treatments, including novel anticancer therapies, medical compounds, vaccines, cosmetics, and a wide array of natural products and extracts. With a dedicated team of scientists, Altogen Labs provides a comprehensive suite of laboratory services, utilizing the latest technologies and methodologies to drive progress in oncology and accelerate drug development. The company offers specialized immuno-oncology services, utilizing advanced humanized and immunodeficient rodent models, including models engrafted with peripheral blood mononuclear cells (PBMC), CD34+ hematopoietic stem cells, and induced pluripotent stem cells (iPSC). These cutting-edge models provide robust platforms for evaluating immune responses, drug efficacy, and toxicity.

With a strong focus on drug discovery and development in oncology, Altogen Labs accelerates the progress of novel therapies by offering over 100 in-house validated xenograft models, including conventional CDX, patient-derived xenografts (PDX), in vitro patient-derived cell cultures (PDC), and patient-derived organoids (PDOrg). One of Altogen Labs’ key strengths is its platform, which allows for the prediction of drug efficacy in genetically characterized, clinically relevant cancer models. This approach, combined with in vivo testing of new cancer therapies in humanized models, delivers the best possible preclinical data.

Altogen’s team conducts extensive toxicity studies (acute, sub-chronic, and chronic) to evaluate compound safety and toxic effects over time. Acute studies focus on short-term impacts, while sub-chronic and chronic studies assess toxicity over months to a year. These comprehensive analyses ensure the safety of potential drug candidates. Understanding potential adverse effects is essential for ensuring clinical efficacy and safety. In vivo efficacy and safety studies utilizing various xenograft models explore different dosage levels and drug administration routes to optimize delivery and biodistribution for investigational new drugs (INDs).

Read more about Altogen Labs immunooncology services

About Altogen Labs

Altogen Labs’ research facility is located in Austin, Texas, and provides a broad range of preclinical and biological CRO services for safety and efficacy studies, supporting early-stage drug discovery and the development of novel therapies. Altogen Labs is a reliable partner for all preclinical research needs. With cutting-edge technologies, an experienced team of scientists, and a commitment to excellence, the company continues to drive innovation in the fields of oncology and immunotherapy.

Contact

Altogen Labs

11200 Menchaca Rd

Austin TX 78748

info@altogenlabs.com

Efficacy and Safety Preclinical Services to Accelerate Research Needs

Altogen Labs, a global biology CRO company, provides preclinical research services for pharmaceutical, biotechnology, and cancer research centers worldwide. In an effort to expedite the development of new anti-cancer medicines, Altogen Labs now provides over 100 in-house validated xenograft models and safety in vivo toxicology services for drug development studies. Both efficacy and safety studies… Continue Reading

Array of Lung Cancer Xenograft Models for Cutting-Edge Oncology Research

Altogen Labs, a preclinical CRO laboratory, has announced the validation of a comprehensive array of 10 lung cancer xenograft models. These models are essential for testing in vivo efficacy of novel therapeutics against lung cancer, elevating the prospects for significant advances in the diagnosis, understanding, and treatment of primary lung carcinoma. Less than 20% of… Continue Reading

Validated preclinical xenograft models for in vivo efficacy testing of INDs

Altogen Labs provides validated preclinical xenograft models for in vivo efficacy testing of Investigational New Drugs (INDs). These research services are conducted under Good Laboratory Practices (GLP) standards. The xenograft models are rigorously validated to ensure reliable and reproducible results. Altogen Labs offers a wide selection of validated CDX and PDX xenograft models, including many… Continue Reading

Toxicology IND Preclinical Research Services

Toxicology IND Preclinical Research Services

Altogen Labs, a preclinical CRO, provides essential safety and efficacy testing for novel medicines (GLP-compliant pharm/tox assays per FDA IND requirements). Company works with renowned academic research organizations and pharma/biotech industry to reduce GLP studies timelines and costs while maintaining high quality and GLP standards. Altogen Labs preclinical CRO services includes efficacy xenograft studies (over… Continue Reading

Validated breast cancer xenograft models

Altogen Labs is a GLP-compliant biotech laboratory that specializes in oncology research studies and provides preclinical testing of new medicines that often require a sequence of experiments utilizing various scientific methods to demonstrate novel compound anti-cancer efficacy, safety, and mechanism of action. Breast cancer is the second leading cancer that causes death in women globally,… Continue Reading

Science Calculators

More calculators and articles at Altogen Labs | Scientific Resources webpage Validated xenograft models: Xenograft Models | Altogen Labs More calculators and articles at Altogen Labs | Scientific Resources webpage Validated xenograft models: Xenograft Models | Altogen Labs More calculators and articles at Altogen Labs | Scientific Resources webpage Validated xenograft models: Xenograft Models |… Continue Reading

100+ Validated Xenograft Models for In Vivo IND Efficacy Testing. Preclinical GLP Research Services by Altogen Labs.

100+ Validated Xenograft Models for In Vivo IND Efficacy Testing. Preclinical GLP Research Services by Altogen Labs.

AUSTIN, Texas – July 28, 2021 – Altogen Labs offers over 100 validated models of cell line-derived xenografts (CDX) and patient-derived xenografts (PDX), including syngeneic xenograft models. Xenograft IND testing services are performed to measure the activity and efficacy of novel anti-cancer compounds based on the rate of engrafted tumor growth. The most recent additions… Continue Reading

Altogen Laboratory Testing of Known Compounds for Cancer Treatment Efficacy

Sodium dichloroacetate (DCA) has been investigated as a novel cancer therapy since 2007 when Bonnet et al published research study demonstrating the efficacy of DCA in treating human cancers by inhibition of mitochondrial pyruvate dehydrogenase kinase (PDK). Altogen Labs, an Austin-based biotechnology and preclinical research company, performed an independent study exploring potential novel and accessible… Continue Reading

How to test the anticancer efficacy of a plant extract

Testing the anticancer efficacy of a plant extract involves a series of in vitro (using cancer cell lines) and in vivo (animal-based) experiments, as well as testing safety and efficacy. The process can be lengthy and requires adherence to scientific and ethical guidelines. Here is an outline of the general procedure: Altogen Labs provides commercially… Continue Reading